User Tools

Site Tools


1p/19q co-deletion unclassified

Last update Nov 30 2019

6: Ginet M, Zaragori T, Marie PY, Roch V, Gauchotte G, Rech F, Blonski M, Lamiral Z, Taillandier L, Imbert L, Verger A. Integration of dynamic parameters in the analysis of (18)F-FDopa PET imaging improves the prediction of molecular features of gliomas. Eur J Nucl Med Mol Imaging. 2019 Sep 16. doi: 10.1007/s00259-019-04509-y. [Epub ahead of print] PubMed PMID: 31529264.

7: Kwon MJ, Kang SY, Cho H, Lee JI, Kim ST, Suh YL. Clinical relevance of molecular subgrouping of gliomatosis cerebri per 2016 WHO classification: a clinicopathological study of 89 cases. Brain Pathol. 2019 Aug 21. doi: 10.1111/bpa.12782. [Epub ahead of print] PubMed PMID: 31435963.

8: Ochirjav E, Enkhbat B, Baldandorj T, Choe G. Reclassification of Mongolian Diffuse Gliomas According to the Revised 2016 World Health Organization Central Nervous System Tumor Classification. J Pathol Transl Med. 2019 Sep;53(5):298-307. doi: 10.4132/jptm.2019.07.15. Epub 2019 Aug 2. PubMed PMID: 31370384; PubMed Central PMCID: PMC6755654.

9: Galldiks N, Brunn A, Fink GR, Langen KJ. Dynamic FET PET Imaging of a “Butterfly” IDH-Wildtype Anaplastic Astrocytoma. Clin Nucl Med. 2019 Oct;44(10):e581-e582. doi: 10.1097/RLU.0000000000002740. PubMed PMID: 31348085.

10: Zhang C, Yu R, Li Z, Song H, Zang D, Deng M, Fan Y, Liu Y, Zhang Y, Qu X. Comprehensive analysis of genes based on chr1p/19q co-deletion reveals a robust 4-gene prognostic signature for lower grade glioma. Cancer Manag Res. 2019 May 29;11:4971-4984. doi: 10.2147/CMAR.S199396. eCollection 2019. PubMed PMID: 31213913; PubMed Central PMCID: PMC6551448.

11: Feyissa AM, Worrell GA, Tatum WO, Chaichana KL, Jentoft ME, Guerrero Cazares H, Ertekin-Taner N, Rosenfeld SS, ReFaey K, Quinones-Hinojosa A. Potential influence of IDH1 mutation and MGMT gene promoter methylation on glioma-related preoperative seizures and postoperative seizure control. Seizure. 2019 Jul;69:283-289. doi: 10.1016/j.seizure.2019.05.018. Epub 2019 May 20. PubMed PMID: 31141785.

12: Tabrizi S, Yeap BY, Sherman JC, Nachtigall LB, Colvin MK, Dworkin M, Fullerton BC, Daartz J, Royce TJ, Oh KS, Batchelor TT, Curry WT, Loeffler JS, Shih HA. Long-term outcomes and late adverse effects of a prospective study on proton radiotherapy for patients with low-grade glioma. Radiother Oncol. 2019 Aug;137:95-101. doi: 10.1016/j.radonc.2019.04.027. Epub 2019 May 10. PubMed PMID: 31082632; PubMed Central PMCID: PMC6642836.

13: Buda M, Saha A, Mazurowski MA. Association of genomic subtypes of lower-grade gliomas with shape features automatically extracted by a deep learning algorithm. Comput Biol Med. 2019 Jun;109:218-225. doi: 10.1016/j.compbiomed.2019.05.002. Epub 2019 May 3. PubMed PMID: 31078126.

14: Burford C, Laxton R, Sidhu Z, Aizpurua M, King A, Bodi I, Ashkan K, Al-Sarraj S. ATRX immunohistochemistry can help refine 'not elsewhere classified' categorisation for grade II/III gliomas. Br J Neurosurg. 2019 Oct;33(5):536-540. doi: 10.1080/02688697.2019.1600657. Epub 2019 Apr 24. PubMed PMID: 31018710.

15: Deluche E, Bessette B, Durand S, Caire F, Rigau V, Robert S, Chaunavel A, Forestier L, Labrousse F, Jauberteau MO, Durand K, Lalloué F. CHI3L1, NTRK2, 1p/19q and IDH Status Predicts Prognosis in Glioma. Cancers (Basel). 2019 Apr 15;11(4). pii: E544. doi: 10.3390/cancers11040544. PubMed PMID: 30991699; PubMed Central PMCID: PMC6521129.

16: Harat M, Blok M, Harat A, Soszyńska K. The impact of adjuvant radiotherapy on molecular prognostic markers in gliomas. Onco Targets Ther. 2019 Mar 26;12:2215-2224. doi: 10.2147/OTT.S200818. eCollection 2019. PubMed PMID: 30988626; PubMed Central PMCID: PMC6441459.

17: Vismara MFM, Donato A, Malara N, Presta I, Donato G. Immunotherapy in gliomas: Are we reckoning without the innate immunity? Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738419843378. doi: 10.1177/2058738419843378. Review. PubMed PMID: 30968718; PubMed Central PMCID: PMC6458670.

18: Kuskucu A, Tuysuz EC, Gurkan S, Demir Z, Yaltirik CK, Ozkan F, Ekici ID, Bayrak OF, Ture U. Co-polysomy of 1p/19q in glial tumors: Retrospective analysis of 221 cases from single center. Gene. 2019 Jun 15;701:161-168. doi: 10.1016/j.gene.2019.02.073. Epub 2019 Mar 5. PubMed PMID: 30849537.

19: Park H, Chun SM, Shim J, Oh JH, Cho EJ, Hwang HS, Lee JY, Kim D, Jang SJ, Nam SJ, Hwang C, Sohn I, Sung CO. Detection of chromosome structural variation by targeted next-generation sequencing and a deep learning application. Sci Rep. 2019 Mar 6;9(1):3644. doi: 10.1038/s41598-019-40364-5. PubMed PMID: 30842562; PubMed Central PMCID: PMC6403216.

20: Tamrakar S, Yashiro M, Kawashima T, Uda T, Terakawa Y, Kuwae Y, Ohsawa M, Ohata K. Clinicopathological Significance of Autophagy-related Proteins and its Association With Genetic Alterations in Gliomas. Anticancer Res. 2019 Mar;39(3):1233-1242. doi: 10.21873/anticanres.13233. PubMed PMID: 30842153.

21: Tiwari N, Tamrazi B, Robison N, Krieger M, Ji J, Tian D. Unusual radiological and histological presentation of a diffuse leptomeningeal glioneuronal tumor (DLGNT) in a 13-year-old girl. Childs Nerv Syst. 2019 Sep;35(9):1609-1614. doi: 10.1007/s00381-019-04074-7. Epub 2019 Feb 15. PubMed PMID: 30770994.

22: Miller AM, Shah RH, Pentsova EI, Pourmaleki M, Briggs S, Distefano N, Zheng Y, Skakodub A, Mehta SA, Campos C, Hsieh WY, Selcuklu SD, Ling L, Meng F, Jing X, Samoila A, Bale TA, Tsui DWY, Grommes C, Viale A, Souweidane MM, Tabar V, Brennan CW, Reiner AS, Rosenblum M, Panageas KS, DeAngelis LM, Young RJ, Berger MF, Mellinghoff IK. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature. 2019 Jan;565(7741):654-658. doi: 10.1038/s41586-019-0882-3. Epub 2019 Jan 23. PubMed PMID: 30675060; PubMed Central PMCID: PMC6457907.

23: Zhou H, Chang K, Bai HX, Xiao B, Su C, Bi WL, Zhang PJ, Senders JT, Vallières M, Kavouridis VK, Boaro A, Arnaout O, Yang L, Huang RY. Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas. J Neurooncol. 2019 Apr;142(2):299-307. doi: 10.1007/s11060-019-03096-0. Epub 2019 Jan 19. PubMed PMID: 30661193; PubMed Central PMCID: PMC6510979.

24: Homma T, Hanashima Y, Maebayashi T, Nakanishi Y, Ishige T, Ohta T, Yoshino A, Hao H. Papillary glioblastoma exhibiting a neuroradiological cyst with a mural nodule: A case report. Medicine (Baltimore). 2019 Jan;98(2):e14102. doi: 10.1097/MD.0000000000014102. PubMed PMID: 30633222; PubMed Central PMCID: PMC6336597.

25: Cicone F, Carideo L, Scaringi C, Arcella A, Giangaspero F, Scopinaro F, Minniti G. (18)F-DOPA uptake does not correlate with IDH mutation status and 1p/19q co-deletion in glioma. Ann Nucl Med. 2019 Apr;33(4):295-302. doi: 10.1007/s12149-018-01328-3. Epub 2019 Jan 3. PubMed PMID: 30607877.

26: Iwadate Y, Matsutani T, Hara A, Hirono S, Ikegami S, Kobayashi M, Ito D, Kawauchi D, Horiguchi K, Tamiya A, Higuchi Y. Eighty percent survival rate at 15 years for 1p/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade. J Neurooncol. 2019 Jan;141(1):205-211. doi: 10.1007/s11060-018-03027-5. Epub 2018 Dec 18. PubMed PMID: 30565028.

27: Andersson U, Degerman S, Dahlin AM, Wibom C, Johansson G, Bondy ML, Melin BS. The association between longer relative leukocyte telomere length and risk of glioma is independent of the potentially confounding factors allergy, BMI, and smoking. Cancer Causes Control. 2019 Feb;30(2):177-185. doi: 10.1007/s10552-018-1120-2. Epub 2018 Dec 17. PubMed PMID: 30560391.

28: Suchorska B, Schüller U, Biczok A, Lenski M, Albert NL, Giese A, Kreth FW, Ertl-Wagner B, Tonn JC, Ingrisch M. Contrast enhancement is a prognostic factor in IDH1/2 mutant, but not in wild-type WHO grade II/III glioma as confirmed by machine learning. Eur J Cancer. 2019 Jan;107:15-27. doi: 10.1016/j.ejca.2018.10.019. Epub 2018 Dec 7. PubMed PMID: 30529899.

29: Geevar T, Pai R, Chacko G, Malepathi K, Patel B, John J, Chacko AG, Balakrishnan R, John S. Molecular profile of tumors with oligodendroglial morphology: Clinical relevance. Neurol India. 2018 Nov-Dec;66(6):1726-1731. doi: 10.4103/0028-3886.246275. PubMed PMID: 30504574.

30: Halani SH, Yousefi S, Velazquez Vega J, Rossi MR, Zhao Z, Amrollahi F, Holder CA, Baxter-Stoltzfus A, Eschbacher J, Griffith B, Olson JJ, Jiang T, Yates JR, Eberhart CG, Poisson LM, Cooper LAD, Brat DJ. Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways. NPJ Precis Oncol. 2018 Nov 6;2:24. doi: 10.1038/s41698-018-0067-9. eCollection 2018. PubMed PMID: 30417117; PubMed Central PMCID: PMC6219505.

31: Tanaka S, Hitotsumatsu T, Sugita Y, Ishido K, Ito O, Hatae R, Akagi Y, Yoshimoto K, Iihara K. Gliosarcoma arising from oligodendroglioma (Oligosarcoma): A case report with genetic analyses. Pathol Int. 2018 Oct;68(10):567-573. doi: 10.1111/pin.12723. Epub 2018 Sep 23. PubMed PMID: 30246385.

32: Garcia CR, Slone SA, Pittman T, St Clair WH, Lightner DD, Villano JL. Comprehensive evaluation of treatment and outcomes of low-grade diffuse gliomas. PLoS One. 2018 Sep 20;13(9):e0203639. doi: 10.1371/journal.pone.0203639. eCollection 2018. PubMed PMID: 30235224; PubMed Central PMCID: PMC6147430.

33: van den Bent MJ, Klein M, Smits M, Reijneveld JC, French PJ, Clement P, de Vos FYF, Wick A, Mulholland PJ, Taphoorn MJB, Lewis J, Weller M, Chinot OL, Kros JM, de Heer I, Verschuere T, Coens C, Golfinopoulos V, Gorlia T, Idbaih A. Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. Lancet Oncol. 2018 Sep;19(9):1170-1179. doi: 10.1016/S1470-2045(18)30362-0. Epub 2018 Aug 13. PubMed PMID: 30115593.

34: Han Y, Xie Z, Zang Y, Zhang S, Gu D, Zhou M, Gevaert O, Wei J, Li C, Chen H, Du J, Liu Z, Dong D, Tian J, Zhou D. Non-invasive genotype prediction of chromosome 1p/19q co-deletion by development and validation of an MRI-based radiomics signature in lower-grade gliomas. J Neurooncol. 2018 Nov;140(2):297-306. doi: 10.1007/s11060-018-2953-y. Epub 2018 Aug 10. PubMed PMID: 30097822.

35: Nambirajan A, Suri V, Kedia S, Goyal K, Malgulwar PB, Khanna G, Panda PK, Gulati S, Garg A, Sharma MC. Paediatric diffuse leptomeningeal tumor with glial and neuronal differentiation harbouring chromosome 1p/19q co-deletion and H3.3 K27M mutation: unusual molecular profile and its therapeutic implications. Brain Tumor Pathol. 2018 Jul;35(3):186-191. doi: 10.1007/s10014-018-0325-0. Epub 2018 Jul 20. PubMed PMID: 30030640.

36: D'Amico RS, Zanazzi G, Wu P, Canoll P, Bruce JN. Pineal region glioblastomas display features of diffuse midline and non-midline gliomas. J Neurooncol. 2018 Oct;140(1):63-73. doi: 10.1007/s11060-018-2931-4. Epub 2018 Jul 10. PubMed PMID: 29992434.

37: Lehrer S, Rheinstein PH, Rosenzweig KE. Loss of MycBP may be associated with the improved survival in 1P co-deletion of lower grade glioma patients. Clin Neurol Neurosurg. 2018 Sep;172:112-115. doi: 10.1016/j.clineuro.2018.07.003. Epub 2018 Jul 5. PubMed PMID: 29986195.

38: Franceschi E, Mura A, De Biase D, Tallini G, Pession A, Foschini MP, Danieli D, Pizzolitto S, Zunarelli E, Lanza G, Bartolini D, Silini EM, Visani M, Di Oto E, Tosoni A, Minichillo S, Lamberti G, Lanese A, Paccapelo A, Bartolini S, Brandes AA. The role of clinical and molecular factors in low-grade gliomas: what is their impact on survival? Future Oncol. 2018 Jul;14(16):1559-1567. doi: 10.2217/fon-2017-0634. Epub 2018 Jun 25. PubMed PMID: 29938525.

39: Kobyakov GL, Absalyamova OV, Poddubskiy AA, Lodygina KS, Kobyakova EA. [The 2016 WHO classification of primary central nervous system tumors: a clinician's view]. Zh Vopr Neirokhir Im N N Burdenko. 2018;82(3):88-96. doi: 10.17116/neiro201882388. Russian. PubMed PMID: 29927430.

40: Lei L, Jiang Z, Zhang G, Cheng Q, Lu H. MGMT promoter methylation and 1p/19q co-deletion of surgically resected pulmonary carcinoid and large-cell neuroendocrine carcinoma. World J Surg Oncol. 2018 Jun 18;16(1):110. doi: 10.1186/s12957-018-1413-7. PubMed PMID: 29914531; PubMed Central PMCID: PMC6007073.

41: Gladitz J, Klink B, Seifert M. Network-based analysis of oligodendrogliomas predicts novel cancer gene candidates within the region of the 1p/19q co-deletion. Acta Neuropathol Commun. 2018 Jun 11;6(1):49. doi: 10.1186/s40478-018-0544-y. PubMed PMID: 29890994; PubMed Central PMCID: PMC5996550.

42: Linzey JR, Marini B, McFadden K, Lorenzana A, Mody R, Robertson PL, Koschmann C. Identification and targeting of an FGFR fusion in a pediatric thalamic “central oligodendroglioma”. NPJ Precis Oncol. 2017 Sep 7;1(1):29. doi: 10.1038/s41698-017-0036-8. eCollection 2017. Erratum in: NPJ Precis Oncol. 2018 Apr 25;2:12. PubMed PMID: 29872711; PubMed Central PMCID: PMC5871816.

43: Deng MY, Sill M, Chiang J, Schittenhelm J, Ebinger M, Schuhmann MU, Monoranu CM, Milde T, Wittmann A, Hartmann C, Sommer C, Paulus W, Gärtner J, Brück W, Rüdiger T, Leipold A, Jaunmuktane Z, Brandner S, Giangaspero F, Nozza P, Mora J, Morales la Madrid A, Cruz Martinez O, Hansford JR, Pietsch T, Tietze A, Hernáiz-Driever P, Stoler I, Capper D, Korshunov A, Ellison DW, von Deimling A, Pfister SM, Sahm F, Jones DTW. Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features. Acta Neuropathol. 2018 Aug;136(2):239-253. doi: 10.1007/s00401-018-1865-4. Epub 2018 May 15. PubMed PMID: 29766299.

44: Wirsching HG, Weiss T, Roth P, Weller M. [Basic principles of diagnosis and treatment of gliomas]. Nervenarzt. 2018 Jun;89(6):692-698. doi: 10.1007/s00115-018-0519-z. Review. German. PubMed PMID: 29679127.

45: Lauber C, Klink B, Seifert M. Comparative analysis of histologically classified oligodendrogliomas reveals characteristic molecular differences between subgroups. BMC Cancer. 2018 Apr 10;18(1):399. doi: 10.1186/s12885-018-4251-7. PubMed PMID: 29631562; PubMed Central PMCID: PMC5892046.

46: Sim J, Nam DH, Kim Y, Lee IH, Choi JW, Sa JK, Suh YL. Comparison of 1p and 19q status of glioblastoma by whole exome sequencing, array-comparative genomic hybridization, and fluorescence in situ hybridization. Med Oncol. 2018 Mar 29;35(5):60. doi: 10.1007/s12032-018-1119-2. PubMed PMID: 29600313.

47: Yamamichi A, Ohka F, Aoki K, Suzuki H, Kato A, Hirano M, Motomura K, Tanahashi K, Chalise L, Maeda S, Wakabayashi T, Kato Y, Natsume A. Immunohistochemical ATRX expression is not a surrogate for 1p19q codeletion. Brain Tumor Pathol. 2018 Apr;35(2):106-113. doi: 10.1007/s10014-018-0312-5. Epub 2018 Mar 17. PubMed PMID: 29550880.

48: Iuchi T, Sugiyama T, Ohira M, Kageyama H, Yokoi S, Sakaida T, Hasegawa Y, Setoguchi T, Itami M. Clinical significance of the 2016 WHO classification in Japanese patients with gliomas. Brain Tumor Pathol. 2018 Apr;35(2):71-80. doi: 10.1007/s10014-018-0309-0. Epub 2018 Feb 22. PubMed PMID: 29470683.

49: Hempel JM, Schittenhelm J, Klose U, Bender B, Bier G, Skardelly M, Tabatabai G, Castaneda Vega S, Ernemann U, Brendle C. In Vivo Molecular Profiling of Human Glioma : Cross-Sectional Observational Study Using Dynamic Susceptibility Contrast Magnetic Resonance Perfusion Imaging. Clin Neuroradiol. 2019 Sep;29(3):479-491. doi: 10.1007/s00062-018-0676-2. Epub 2018 Feb 21. PubMed PMID: 29468261.

50: Labreche K, Kinnersley B, Berzero G, Di Stefano AL, Rahimian A, Detrait I, Marie Y, Grenier-Boley B, Hoang-Xuan K, Delattre JY, Idbaih A, Houlston RS, Sanson M. Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci. Acta Neuropathol. 2018 May;135(5):743-755. doi: 10.1007/s00401-018-1825-z. Epub 2018 Feb 19. PubMed PMID: 29460007; PubMed Central PMCID: PMC5904227.

51: Han F, Zhang J, Ma S, Chen X, Liu W, He X, Fei Z, Wang Y. Altered capicua transcriptional repressor gene expression exhibits distinct prognostic value for isocitrate dehydrogenase-mutant oligodendroglial tumors. Oncol Lett. 2018 Feb;15(2):1459-1468. doi: 10.3892/ol.2017.7460. Epub 2017 Nov 21. PubMed PMID: 29434837; PubMed Central PMCID: PMC5774460.

52: Komori T, Muragaki Y, Chernov MF. Pathology and Genetics of Gliomas. Prog Neurol Surg. 2018;31:1-37. doi: 10.1159/000466835. Epub 2018 Jan 25. Review. PubMed PMID: 29393190.

53: Soffietti R, Franchino F, Magistrello M, Pellerino A, Rudà R. Perspectives of Personalized Chemotherapy of Gliomas Based on Molecular Tumor Profiling. Prog Neurol Surg. 2018;31:168-179. doi: 10.1159/000467378. Epub 2018 Jan 25. Review. PubMed PMID: 29393185.

54: Zhao XW, Zhan YB, Bao JJ, Zhou JQ, Zhang FJ, Bin Y, Bai YH, Wang YM, Zhang ZY, Liu XZ. Clinicopathological analysis of HOXD4 expression in diffuse gliomas and its correlation with IDH mutations and 1p/19q co-deletion. Oncotarget. 2017 Dec 18;8(70):115657-115666. doi: 10.18632/oncotarget.23371. eCollection 2017 Dec 29. PubMed PMID: 29383189; PubMed Central PMCID: PMC5777801.

55: Wang K, Wang Y, Fan X, Li Y, Liu X, Wang J, Ai L, Dai J, Jiang T. Regional specificity of 1p/19q co-deletion combined with radiological features for predicting the survival outcomes of anaplastic oligodendroglial tumor patients. J Neurooncol. 2018 Feb;136(3):523-531. doi: 10.1007/s11060-017-2673-8. Epub 2017 Dec 11. PubMed PMID: 29230668.

56: Rogers TW, Toor G, Drummond K, Love C, Field K, Asher R, Tsui A, Buckland M, Gonzales M. The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas. J Neurooncol. 2018 Mar;137(1):181-189. doi: 10.1007/s11060-017-2710-7. Epub 2017 Dec 7. PubMed PMID: 29218432.

57: Li Z, Piao YS, Zhang LY, Wang LM, Wang DD, Fu YJ, Cai YN, Lu DH. [Application of ATRX in diagnosis and prognostic evaluation of glioma]. Zhonghua Bing Li Xue Za Zhi. 2017 Oct 8;46(10):690-694. doi: 10.3760/cma.j.issn.0529-5807.2017.10.006. Chinese. PubMed PMID: 29050070.

58: Liu CC, Zhang LY, Wang LM, Wang DD, Fu YJ, Cai YN, Lu DH, Piao YS. [Diagnostic and prognostic roles of loss of CIC protein expression in oligodendroglial tumors]. Zhonghua Bing Li Xue Za Zhi. 2017 Oct 8;46(10):679-683. doi: 10.3760/cma.j.issn.0529-5807.2017.10.004. Chinese. PubMed PMID: 29050068.

59: Verger A, Stoffels G, Bauer EK, Lohmann P, Blau T, Fink GR, Neumaier B, Shah NJ, Langen KJ, Galldiks N. Static and dynamic (18)F-FET PET for the characterization of gliomas defined by IDH and 1p/19q status. Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):443-451. doi: 10.1007/s00259-017-3846-6. Epub 2017 Oct 17. PubMed PMID: 29043400.

60: Suchorska B, Giese A, Biczok A, Unterrainer M, Weller M, Drexler M, Bartenstein P, Schüller U, Tonn JC, Albert NL. Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma. Neuro Oncol. 2018 Jan 22;20(2):279-288. doi: 10.1093/neuonc/nox153. PubMed PMID: 29016996; PubMed Central PMCID: PMC5777500.

61: Rajeswarie RT, Rao S, Nandeesh BN, Yasha TC, Santosh V. A simple algorithmic approach using histology and immunohistochemistry for the current classification of adult diffuse glioma in a resource-limited set-up. J Clin Pathol. 2018 Apr;71(4):323-329. doi: 10.1136/jclinpath-2017-204638. Epub 2017 Aug 11. PubMed PMID: 28801347.

62: Khan IN, Ullah N, Hussein D, Saini KS. Current and emerging biomarkers in tumors of the central nervous system: Possible diagnostic, prognostic and therapeutic applications. Semin Cancer Biol. 2018 Oct;52(Pt 1):85-102. doi: 10.1016/j.semcancer.2017.07.004. Epub 2017 Jul 31. Review. PubMed PMID: 28774835.

63: Sorge C, Li R, Singh S, Reddy AT, Solomon DA, Perry A, Friedman GK. Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature. Pediatr Blood Cancer. 2017 Dec;64(12). doi: 10.1002/pbc.26708. Epub 2017 Jul 11. Review. PubMed PMID: 28696020.

64: van den Bent MJ, Smits M, Kros JM, Chang SM. Diffuse Infiltrating Oligodendroglioma and Astrocytoma. J Clin Oncol. 2017 Jul 20;35(21):2394-2401. doi: 10.1200/JCO.2017.72.6737. Epub 2017 Jun 22. Review. PubMed PMID: 28640702.

65: Staedtke V, Dzaye O, Holdhoff M. Actionable molecular biomarkers in primary brain tumors. Trends Cancer. 2016 Jul;2(7):338-349. doi: 10.1016/j.trecan.2016.06.003. Review. PubMed PMID: 28603776; PubMed Central PMCID: PMC5461965.

66: Leu K, Ott GA, Lai A, Nghiemphu PL, Pope WB, Yong WH, Liau LM, Cloughesy TF, Ellingson BM. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas. J Neurooncol. 2017 Aug;134(1):177-188. doi: 10.1007/s11060-017-2506-9. Epub 2017 May 25. PubMed PMID: 28547590.

67: Eseonu CI, Eguia F, ReFaey K, Garcia O, Rodriguez FJ, Chaichana K, Quinones-Hinojosa A. Comparative volumetric analysis of the extent of resection of molecularly and histologically distinct low grade gliomas and its role on survival. J Neurooncol. 2017 Aug;134(1):65-74. doi: 10.1007/s11060-017-2486-9. Epub 2017 May 19. PubMed PMID: 28527004.

68: Lin Y, Xing Z, She D, Yang X, Zheng Y, Xiao Z, Wang X, Cao D. IDH mutant and 1p/19q co-deleted oligodendrogliomas: tumor grade stratification using diffusion-, susceptibility-, and perfusion-weighted MRI. Neuroradiology. 2017 Jun;59(6):555-562. doi: 10.1007/s00234-017-1839-6. Epub 2017 May 4. PubMed PMID: 28474187; PubMed Central PMCID: PMC5446560.

69: Mazurowski MA, Clark K, Czarnek NM, Shamsesfandabadi P, Peters KB, Saha A. Radiogenomics of lower-grade glioma: algorithmically-assessed tumor shape is associated with tumor genomic subtypes and patient outcomes in a multi-institutional study with The Cancer Genome Atlas data. J Neurooncol. 2017 May;133(1):27-35. doi: 10.1007/s11060-017-2420-1. Epub 2017 May 3. PubMed PMID: 28470431.

70: Afyounian E, Annala M, Nykter M. Segmentum: a tool for copy number analysis of cancer genomes. BMC Bioinformatics. 2017 Apr 13;18(1):215. doi: 10.1186/s12859-017-1626-8. PubMed PMID: 28407731; PubMed Central PMCID: PMC5390478.

71: Holdhoff M, Cairncross GJ, Kollmeyer TM, Zhang M, Zhang P, Mehta MP, Werner-Wasik M, Souhami L, Bahary JP, Kwok Y, Hartford AC, Chakravarti A, Yegnasubramanian S, Vogelstein B, Papadopoulos N, Kinzler K, Jenkins RB, Bettegowda C. Genetic landscape of extreme responders with anaplastic oligodendroglioma. Oncotarget. 2017 May 30;8(22):35523-35531. doi: 10.18632/oncotarget.16773. PubMed PMID: 28388591; PubMed Central PMCID: PMC5482595.

72: Hu X, Martinez-Ledesma E, Zheng S, Kim H, Barthel F, Jiang T, Hess KR, Verhaak RGW. Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma. Neuro Oncol. 2017 Jun 1;19(6):786-795. doi: 10.1093/neuonc/now285. PubMed PMID: 28340142; PubMed Central PMCID: PMC5464432.

73: Chen R, Smith-Cohn M, Cohen AL, Colman H. Glioma Subclassifications and Their Clinical Significance. Neurotherapeutics. 2017 Apr;14(2):284-297. doi: 10.1007/s13311-017-0519-x. Review. PubMed PMID: 28281173; PubMed Central PMCID: PMC5398991.

74: Pai T, Epari S, Desai S, Wadile A, Gupta T, Goda JS, Moiyadi A, Shetty P, Kane S, Jalali R. Histological spectrum of oligodendroglial tumors: Only a subset shows 1p/19q codeletion. Neurol India. 2017 Jan-Feb;65(1):113-120. doi: 10.4103/0028-3886.198195. PubMed PMID: 28084254.

75: Hua W, Mao Y. [Advance of molecular subtyping and precise treatment for gliomas]. Zhonghua Wai Ke Za Zhi. 2017 Jan 1;55(1):63-66. doi: 10.3760/cma.j.issn.0529-5815.2017.01.016. Review. Chinese. PubMed PMID: 28056258.

76: Zhang YA, Zhou Y, Luo X, Song K, Ma X, Sathe A, Girard L, Xiao G, Gazdar AF. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas. EBioMedicine. 2016 Nov;13:80-89. doi: 10.1016/j.ebiom.2016.10.040. Epub 2016 Oct 28. PubMed PMID: 27840009; PubMed Central PMCID: PMC5264450.

77: Otani R, Uzuka T, Ueki K. Classification of adult diffuse gliomas by molecular markers-a short review with historical footnote. Jpn J Clin Oncol. 2017 Jan;47(1):2-6. doi: 10.1093/jjco/hyw142. Epub 2016 Oct 31. Review. PubMed PMID: 27799281.

78: Mellai M, Annovazzi L, Senetta R, Dell'Aglio C, Mazzucco M, Cassoni P, Schiffer D. Diagnostic revision of 206 adult gliomas (including 40 oligoastrocytomas) based on ATRX, IDH1/2 and 1p/19q status. J Neurooncol. 2017 Jan;131(2):213-222. doi: 10.1007/s11060-016-2296-5. Epub 2016 Oct 28. PubMed PMID: 27796734.

79: Fina F, Barets D, Colin C, Bouvier C, Padovani L, Nanni-Metellus I, Ouafik L, Scavarda D, Korshunov A, Jones DT, Figarella-Branger D. Droplet digital PCR is a powerful technique to demonstrate frequent FGFR1 duplication in dysembryoplastic neuroepithelial tumors. Oncotarget. 2017 Jan 10;8(2):2104-2113. doi: 10.18632/oncotarget.12881. PubMed PMID: 27791984; PubMed Central PMCID: PMC5356784.

80: Bielle F, Ducray F, Mokhtari K, Dehais C, Adle-Biassette H, Carpentier C, Chanut A, Polivka M, Poggioli S, Rosenberg S, Giry M, Marie Y, Duyckaerts C, Sanson M, Figarella-Branger D, Idbaih A; Pola Network. Tumor cells with neuronal intermediate progenitor features define a subgroup of 1p/19q co-deleted anaplastic gliomas. Brain Pathol. 2017 Sep;27(5):567-579. doi: 10.1111/bpa.12434. Epub 2016 Oct 28. PubMed PMID: 27543943.

81: Rao S, Sravya P, Chandran C, Saini J, Somanna S, Santosh V. Granular cells in oligodendroglioma suggest a neoplastic change rather than a reactive phenomenon: case report with molecular characterisation. Brain Tumor Pathol. 2017 Jan;34(1):42-47. doi: 10.1007/s10014-016-0273-5. Epub 2016 Oct 13. PubMed PMID: 27738816.

82: Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Kantor G, Taphoorn MJB, Hassel MB, Hartmann C, Ryan G, Capper D, Kros JM, Kurscheid S, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg JE, Feuvret L, Reijneveld JC, Chinot O, Gijtenbeek JMM, Rossiter JP, Dif N, Balana C, Bravo-Marques J, Clement PM, Marosi C, Tzuk-Shina T, Nordal RA, Rees J, Lacombe D, Mason WP, Stupp R. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016 Nov;17(11):1521-1532. doi: 10.1016/S1470-2045(16)30313-8. Epub 2016 Sep 27. PubMed PMID: 27686946; PubMed Central PMCID: PMC5124485.

83: Chen B, Liang T, Yang P, Wang H, Liu Y, Yang F, You G. Classifying lower grade glioma cases according to whole genome gene expression. Oncotarget. 2016 Nov 8;7(45):74031-74042. doi: 10.18632/oncotarget.12188. PubMed PMID: 27677590; PubMed Central PMCID: PMC5342033.

84: Ohtani R, Uzuka T, Ueki K. [1p/19q co-deletion]. Nihon Rinsho. 2016 Sep;74 Suppl 7:122-125. Japanese. PubMed PMID: 30634741.

85: Wirsching HG, Weller M. The Role of Molecular Diagnostics in the Management of Patients with Gliomas. Curr Treat Options Oncol. 2016 Oct;17(10):51. doi: 10.1007/s11864-016-0430-4. Review. PubMed PMID: 27501915.

86: Demeulenaere M, Duerinck J, DU Four S, Fostier K, Michotte A, Neyns B. Bone Marrow Metastases from a 1p/19q Co-deleted Oligodendroglioma - A Case Report. Anticancer Res. 2016 Aug;36(8):4145-9. PubMed PMID: 27466523.

87: Dubbink HJ, Atmodimedjo PN, van Marion R, Krol NMG, Riegman PHJ, Kros JM, van den Bent MJ, Dinjens WNM. Diagnostic Detection of Allelic Losses and Imbalances by Next-Generation Sequencing: 1p/19q Co-Deletion Analysis of Gliomas. J Mol Diagn. 2016 Sep;18(5):775-786. doi: 10.1016/j.jmoldx.2016.06.002. Epub 2016 Jul 25. Erratum in: J Mol Diagn. 2016 Nov;18(6):933. PubMed PMID: 27461031.

88: Kawaguchi T, Sonoda Y, Shibahara I, Saito R, Kanamori M, Kumabe T, Tominaga T. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion. J Neurooncol. 2016 Sep;129(3):505-514. doi: 10.1007/s11060-016-2201-2. Epub 2016 Jul 11. PubMed PMID: 27401154.

89: Wick W, Roth P, Hartmann C, Hau P, Nakamura M, Stockhammer F, Sabel MC, Wick A, Koeppen S, Ketter R, Vajkoczy P, Eyupoglu I, Kalff R, Pietsch T, Happold C, Galldiks N, Schmidt-Graf F, Bamberg M, Reifenberger G, Platten M, von Deimling A, Meisner C, Wiestler B, Weller M; Neurooncology Working Group (NOA) of the German Cancer Society. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro Oncol. 2016 Nov;18(11):1529-1537. Epub 2016 Jul 1. Erratum in: Neuro Oncol. 2016 Nov;18(11):e1. PubMed PMID: 27370396; PubMed Central PMCID: PMC5063521.

90: Shoji T, Saito R, Kanamori M, Sonoda Y, Watanabe M, Tominaga T. Sarcoma-like tumor originating from oligodendroglioma. Brain Tumor Pathol. 2016 Oct;33(4):255-260. Epub 2016 Jun 22. PubMed PMID: 27333891.

91: Shahid M, Cho KM, Nguyen MN, Choi TG, Jo YH, Aryal SN, Yoo JY, Yun HR, Lee JW, Eun YG, Lee JS, Kang I, Ha J, Yoon HJ, Kim SY, Kim SS. Prognostic value and their clinical implication of 89-gene signature in glioma. Oncotarget. 2016 Aug 9;7(32):51237-51250. doi: 10.18632/oncotarget.9983. PubMed PMID: 27323413; PubMed Central PMCID: PMC5239472.

92: Wang HY, Tang K, Liang TY, Zhang WZ, Li JY, Wang W, Hu HM, Li MY, Wang HQ, He XZ, Zhu ZY, Liu YW, Zhang SZ. The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas. J Exp Clin Cancer Res. 2016 May 31;35:86. doi: 10.1186/s13046-016-0362-7. PubMed PMID: 27245697; PubMed Central PMCID: PMC4888668.

93: Grimm SA, Chamberlain MC. Anaplastic astrocytoma. CNS Oncol. 2016 Jul;5(3):145-57. doi: 10.2217/cns-2016-0002. Epub 2016 May 27. Review. PubMed PMID: 27230974; PubMed Central PMCID: PMC6042632.

94: Figarella-Branger D, Mokhtari K, Dehais C, Carpentier C, Colin C, Jouvet A, Uro-Coste E, Forest F, Maurage CA, Vignaud JM, Polivka M, Lechapt-Zalcman E, Eimer S, Viennet G, Quintin-Roué I, Aubriot-Lorton MH, Diebold MD, Loussouarn D, Lacroix C, Rigau V, Laquerrière A, Vandenbos F, Michalak S, Sevestre H, Peoch M, Labrousse F, Christov C, Kemeny JL, Chenard MP, Chiforeanu D, Ducray F, Idbaih A, Delattre JY; POLA Network. Mitotic index, microvascular proliferation, and necrosis define 3 pathological subgroups of prognostic relevance among 1p/19q co-deleted anaplastic oligodendrogliomas. Neuro Oncol. 2016 Jun;18(6):888-90. doi: 10.1093/neuonc/now085. PubMed PMID: 27175000; PubMed Central PMCID: PMC4864268.

95: Kamoun A, Idbaih A, Dehais C, Elarouci N, Carpentier C, Letouzé E, Colin C, Mokhtari K, Jouvet A, Uro-Coste E, Martin-Duverneuil N, Sanson M, Delattre JY, Figarella-Branger D, de Reyniès A, Ducray F; POLA network. Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas. Nat Commun. 2016 Apr 19;7:11263. doi: 10.1038/ncomms11263. PubMed PMID: 27090007; PubMed Central PMCID: PMC4838899.

96: Duregon E, Bertero L, Pittaro A, Soffietti R, Rudà R, Trevisan M, Papotti M, Ventura L, Senetta R, Cassoni P. Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas. Oncotarget. 2016 Apr 19;7(16):21190-8. doi: 10.18632/oncotarget.8498. PubMed PMID: 27049832; PubMed Central PMCID: PMC5008278.

97: Bonnet C, Thomas L, Psimaras D, Bielle F, Vauléon E, Loiseau H, Cartalat-Carel S, Meyronet D, Dehais C, Honnorat J, Sanson M, Ducray F. Characteristics of gliomas in patients with somatic IDH mosaicism. Acta Neuropathol Commun. 2016 Mar 31;4:31. doi: 10.1186/s40478-016-0302-y. PubMed PMID: 27036230; PubMed Central PMCID: PMC4818526.

98: Masui K, Komori T. [Molecular Genetics as Best Evidence in Glioma Diagnostics]. Brain Nerve. 2016 Mar;68(3):253-61. doi: 10.11477/mf.1416200386. Review. Japanese. PubMed PMID: 27001774.

99: Takano S, Ishikawa E, Sakamoto N, Matsuda M, Akutsu H, Noguchi M, Kato Y, Yamamoto T, Matsumura A. Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas. Brain Tumor Pathol. 2016 Apr;33(2):107-16. doi: 10.1007/s10014-016-0260-x. Epub 2016 Mar 11. PubMed PMID: 26968173.

100: Sathornsumetee S, Cheunsuchon P, Sangruchi T. High Carbonic Anhydrase-9 Expression Identifies a Subset of 1p/19q Co-Deletion and Favorable Prognosis in Oligodendroglioma. World Neurosurg. 2016 Jul;91:518-523.e1. doi: 10.1016/j.wneu.2016.02.069. Epub 2016 Mar 4. PubMed PMID: 26960282.

101: Yang P, Cai J, Yan W, Zhang W, Wang Y, Chen B, Li G, Li S, Wu C, Yao K, Li W, Peng X, You Y, Chen L, Jiang C, Qiu X, Jiang T; CGGA project. Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas. Neuro Oncol. 2016 Aug;18(8):1099-108. doi: 10.1093/neuonc/now021. Epub 2016 Mar 7. PubMed PMID: 26957363; PubMed Central PMCID: PMC4933482.

102: Berger MS, Hervey-Jumper S, Wick W. Astrocytic gliomas WHO grades II and III. Handb Clin Neurol. 2016;134:345-60. doi: 10.1016/B978-0-12-802997-8.00021-9. Review. PubMed PMID: 26948365.

103: Masui K, Mischel PS, Reifenberger G. Molecular classification of gliomas. Handb Clin Neurol. 2016;134:97-120. doi: 10.1016/B978-0-12-802997-8.00006-2. Review. PubMed PMID: 26948350.

104: Li Y, Zeng T, Li B, Luo B, Li Z. [Clinicopathologic characteristics of unusual rhabdoid glioblastoma]. Zhonghua Bing Li Xue Za Zhi. 2015 Nov;44(11):772-7. Chinese. PubMed PMID: 26888386.

105: Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, Rao AA, Grifford M, Cherniack AD, Zhang H, Poisson L, Carlotti CG Jr, Tirapelli DP, Rao A, Mikkelsen T, Lau CC, Yung WK, Rabadan R, Huse J, Brat DJ, Lehman NL, Barnholtz-Sloan JS, Zheng S, Hess K, Rao G, Meyerson M, Beroukhim R, Cooper L, Akbani R, Wrensch M, Haussler D, Aldape KD, Laird PW, Gutmann DH; TCGA Research Network, Noushmehr H, Iavarone A, Verhaak RG. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell. 2016 Jan 28;164(3):550-63. doi: 10.1016/j.cell.2015.12.028. PubMed PMID: 26824661; PubMed Central PMCID: PMC4754110.

106: Jiang H, Zhang Z, Ren X, Zeng W, Wang J, Lin S. Tumor cell-specific chromosomal abnormality in the vascular endothelial cells of anaplastic oligodendroglioma. J Neurosurg. 2016 Oct;125(4):995-1001. Epub 2016 Jan 15. PubMed PMID: 26771849.

107: Hinrichs BH, Newman S, Appin CL, Dunn W, Cooper L, Pauly R, Kowalski J, Rossi MR, Brat DJ. Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups. Acta Neuropathol Commun. 2016 Jan 13;4:4. doi: 10.1186/s40478-015-0270-7. PubMed PMID: 26757882; PubMed Central PMCID: PMC4711079.

108: Ikemura M, Shibahara J, Mukasa A, Takayanagi S, Aihara K, Saito N, Aburatani H, Fukayama M. Utility of ATRX immunohistochemistry in diagnosis of adult diffuse gliomas. Histopathology. 2016 Aug;69(2):260-7. doi: 10.1111/his.12927. Epub 2016 Feb 23. PubMed PMID: 26741321.

109: Polivka J Jr, Polivka J, Repik T, Rohan V, Hes O, Topolcan O. Co-deletion of 1p/19q as Prognostic and Predictive Biomarker for Patients in West Bohemia with Anaplastic Oligodendroglioma. Anticancer Res. 2016 Jan;36(1):471-6. PubMed PMID: 26722084.

110: Liu Y, Hu H, Zhang C, Wang Z, Li M, Jiang T. Integrated analysis identified genes associated with a favorable prognosis in oligodendrogliomas. Genes Chromosomes Cancer. 2016 Feb;55(2):169-76. doi: 10.1002/gcc.22323. Epub 2015 Nov 6. PubMed PMID: 26542540.

111: Nahed BV, Redjal N, Brat DJ, Chi AS, Oh K, Batchelor TT, Ryken TC, Kalkanis SN, Olson JJ. Management of patients with recurrence of diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline. J Neurooncol. 2015 Dec;125(3):609-30. doi: 10.1007/s11060-015-1910-2. Epub 2015 Nov 3. Review. PubMed PMID: 26530264.

112: Ziu M, Kalkanis SN, Gilbert M, Ryken TC, Olson JJ. The role of initial chemotherapy for the treatment of adults with diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline. J Neurooncol. 2015 Dec;125(3):585-607. doi: 10.1007/s11060-015-1931-x. Epub 2015 Nov 3. Review. PubMed PMID: 26530261.

113: Yuh WT, Chung CK, Park SH. Primary Spinal Cord Oligodendroglioma with Postoperative Adjuvant Radiotherapy: A Case Report. Korean J Spine. 2015 Sep;12(3):160-4. doi: 10.14245/kjs.2015.12.3.160. Epub 2015 Sep 30. PubMed PMID: 26512274; PubMed Central PMCID: PMC4623174.

114: Suzuki Y, Takahashi-Fujigasaki J, Akasaki Y, Matsushima S, Mori R, Karagiozov K, Joki T, Ikeuchi S, Ikegami M, Manome Y, Murayama Y. BRAF V600E-mutated diffuse glioma in an adult patient: a case report and review. Brain Tumor Pathol. 2016 Jan;33(1):40-9. doi: 10.1007/s10014-015-0234-4. Epub 2015 Oct 7. Review. PubMed PMID: 26445861.

115: Jaber M, Wölfer J, Ewelt C, Holling M, Hasselblatt M, Niederstadt T, Zoubi T, Weckesser M, Stummer W. The Value of 5-Aminolevulinic Acid in Low-grade Gliomas and High-grade Gliomas Lacking Glioblastoma Imaging Features: An Analysis Based on Fluorescence, Magnetic Resonance Imaging, 18F-Fluoroethyl Tyrosine Positron Emission Tomography, and Tumor Molecular Factors. Neurosurgery. 2016 Mar;78(3):401-11; discussion 411. doi: 10.1227/NEU.0000000000001020. PubMed PMID: 26366972; PubMed Central PMCID: PMC4747980.

116: Komori T. Pathology and Genetics of Diffuse Gliomas in Adults. Neurol Med Chir (Tokyo). 2015;55 Suppl 1:28-37. PubMed PMID: 26236800.

117: Matsumura N, Nobusawa S, Ikota H, Hirato J, Hirose T, Yokoo H, Nakazato Y. Coexpression of cyclin D1 and alpha-internexin in oligodendroglial tumors. Brain Tumor Pathol. 2015 Oct;32(4):261-7. doi: 10.1007/s10014-015-0228-2. Epub 2015 Aug 2. PubMed PMID: 26233522.

118: Foote MB, Papadopoulos N, Diaz LA Jr. Genetic Classification of Gliomas: Refining Histopathology. Cancer Cell. 2015 Jul 13;28(1):9-11. doi: 10.1016/j.ccell.2015.06.014. PubMed PMID: 26175411.

119: Alentorn A, Duran-Peña A, Pingle SC, Piccioni DE, Idbaih A, Kesari S. Molecular profiling of gliomas: potential therapeutic implications. Expert Rev Anticancer Ther. 2015;15(8):955-62. doi: 10.1586/14737140.2015.1062368. Epub 2015 Jun 28. Review. PubMed PMID: 26118895.

120: Labreche K, Simeonova I, Kamoun A, Gleize V, Chubb D, Letouzé E, Riazalhosseini Y, Dobbins SE, Elarouci N, Ducray F, de Reyniès A, Zelenika D, Wardell CP, Frampton M, Saulnier O, Pastinen T, Hallout S, Figarella-Branger D, Dehais C, Idbaih A, Mokhtari K, Delattre JY, Huillard E, Mark Lathrop G, Sanson M, Houlston RS; POLA Network. TCF12 is mutated in anaplastic oligodendroglioma. Nat Commun. 2015 Jun 12;6:7207. doi: 10.1038/ncomms8207. PubMed PMID: 26068201; PubMed Central PMCID: PMC4490400.

121: Appin CL, Brat DJ. Biomarker-driven diagnosis of diffuse gliomas. Mol Aspects Med. 2015 Nov;45:87-96. doi: 10.1016/j.mam.2015.05.002. Epub 2015 May 21. Review. PubMed PMID: 26004297.

122: Odia Y, Varma H, Tsankova NM. Biphasic IDH1 phenotype in a diffusely infiltrating glioma: implications for pathogenesis, treatment and prognosis. Clin Neuropathol. 2015 Sep-Oct;34(5):282-7. doi: 10.5414/NP300832. PubMed PMID: 25907263.

123: Kumar A, Pathak P, Purkait S, Faruq M, Jha P, Mallick S, Suri V, Sharma MC, Suri A, Sarkar C. Oncogenic KIAA1549-BRAF fusion with activation of the MAPK/ERK pathway in pediatric oligodendrogliomas. Cancer Genet. 2015 Mar;208(3):91-5. doi: 10.1016/j.cancergen.2015.01.009. Epub 2015 Feb 20. PubMed PMID: 25794445.

124: Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M, Felsberg J, Beyer U, Löffler-Wirth H, Kaulich K, Steinbach JP, Hartmann C, Gramatzki D, Schramm J, Westphal M, Schackert G, Simon M, Martens T, Boström J, Hagel C, Sabel M, Krex D, Tonn JC, Wick W, Noell S, Schlegel U, Radlwimmer B, Pietsch T, Loeffler M, von Deimling A, Binder H, Reifenberger G. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol. 2015 May;129(5):679-93. doi: 10.1007/s00401-015-1409-0. Epub 2015 Mar 18. PubMed PMID: 25783747.

125: Komori T. Pathology and genetics of diffuse gliomas in adults. Neurol Med Chir (Tokyo). 2015;55(1):28-37. doi: 10.2176/nmc.ra.2014-0229. Epub 2014 Dec 20. Review. PubMed PMID: 25744348; PubMed Central PMCID: PMC4533400.

126: Olar A, Wani KM, Alfaro-Munoz KD, Heathcock LE, van Thuijl HF, Gilbert MR, Armstrong TS, Sulman EP, Cahill DP, Vera-Bolanos E, Yuan Y, Reijneveld JC, Ylstra B, Wesseling P, Aldape KD. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol. 2015 Apr;129(4):585-96. doi: 10.1007/s00401-015-1398-z. Epub 2015 Feb 21. PubMed PMID: 25701198; PubMed Central PMCID: PMC4369189.

127: Erdem-Eraslan L, Heijsman D, de Wit M, Kremer A, Sacchetti A, van der Spek PJ, Sillevis Smitt PA, French PJ. Tumor-specific mutations in low-frequency genes affect their functional properties. J Neurooncol. 2015 May;122(3):461-70. doi: 10.1007/s11060-015-1741-1. Epub 2015 Feb 19. PubMed PMID: 25694352; PubMed Central PMCID: PMC4436689.

128: Zhang ZY, Chan AK, Ng HK, Ding XJ, Li YX, Shi ZF, Zhu W, Zhong P, Wang Y, Mao Y, Yao Y, Zhou LF. Surgically treated incidentally discovered low-grade gliomas are mostly IDH mutated and 1p19q co-deleted with favorable prognosis. Int J Clin Exp Pathol. 2014 Dec 1;7(12):8627-36. eCollection 2014. PubMed PMID: 25674227; PubMed Central PMCID: PMC4313984.

129: Perez-Janices N, Blanco-Luquin I, Tuñón MT, Barba-Ramos E, Ibáñez B, Zazpe-Cenoz I, Martinez-Aguillo M, Hernandez B, Martínez-Lopez E, Fernández AF, Mercado MR, Cabada T, Escors D, Megias D, Guerrero-Setas D. EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas. Oncotarget. 2015 Jan 1;6(1):368-80. PubMed PMID: 25621889; PubMed Central PMCID: PMC4381601.

130: Yao K, Duan Z, Hu Z, Bian Y, Qi X. [Correlation of chromosome 1p and 19q status and expression of R132H mutant IDH1 protein in oligodendroglial tumors]. Zhonghua Bing Li Xue Za Zhi. 2014 Oct;43(10):663-7. Chinese. PubMed PMID: 25567591.

131: Ahluwalia MS, Xie H, Dahiya S, Hashemi-Sadraei N, Schiff D, Fisher PG, Chamberlain MC, Pannullo S, Newton HB, Brewer C, Wood L, Prayson R, Elson P, Peereboom DM. Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study. J Neurooncol. 2015 Mar;122(1):111-9. doi: 10.1007/s11060-014-1684-y. Epub 2014 Dec 23. PubMed PMID: 25534576.

132: Khan KA, Abbasi AN, Ali N. Treatment updates regarding anaplastic oligodendroglioma and anaplastic oligoastrocytoma. J Coll Physicians Surg Pak. 2014 Dec;24(12):935-9. doi: 12.2014/JCPSP.935939. Review. PubMed PMID: 25523732.

133: Borodovsky A, Meeker AK, Kirkness EF, Zhao Q, Eberhart CG, Gallia GL, Riggins GJ. A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeres. J Neurooncol. 2015 Feb;121(3):479-87. doi: 10.1007/s11060-014-1672-2. Epub 2014 Dec 4. PubMed PMID: 25471051; PubMed Central PMCID: PMC4648276.

134: Figarella-Branger D, Mokhtari K, Colin C, Uro-Coste E, Jouvet A, Dehais C, Carpentier C, Villa C, Maurage CA, Eimer S, Polivka M, Vignaud JM, Laquerriere A, Sevestre H, Lechapt-Zalcman E, Quintin-Roué I, Aubriot-Lorton MH, Diebold MD, Viennet G, Adam C, Loussouarn D, Michalak S, Rigau V, Heitzmann A, Vandenbos F, Forest F, Chiforeanu D, Tortel MC, Labrousse F, Chenard MP, Nguyen AT, Varlet P, Kemeny JL, Levillain PM, Cazals-Hatem D, Richard P, Delattre JY; POLA Network. Prognostic Relevance of Histomolecular Classification of Diffuse Adult High-Grade Gliomas with Necrosis. Brain Pathol. 2015 Jul;25(4):418-28. doi: 10.1111/bpa.12227. Epub 2014 Dec 31. PubMed PMID: 25407774.

135: Yu T, Kang HC, Lim DH, Kim IH, Chung WK, Suh CO, Choi BO, Cho KH, Cho JH, Kim JH, Park CK, Hong YK, Kim IA. Pattern of care of anaplastic oligodendroglioma and oligoastrocytoma in a Korean population: the Korean Radiation Oncology Group study 13-12. J Neurooncol. 2015 Feb;121(3):531-9. doi: 10.1007/s11060-014-1660-6. Epub 2014 Nov 13. PubMed PMID: 25391968.

136: Taal W, van der Rijt CC, Dinjens WN, Sillevis Smitt PA, Wertenbroek AA, Bromberg JE, van Heuvel I, Kros JM, van den Bent MJ. Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics. J Neurooncol. 2015 Jan;121(2):365-72. doi: 10.1007/s11060-014-1641-9. Epub 2014 Oct 26. PubMed PMID: 25344884.

137: van Thuijl HF, Scheinin I, Sie D, Alentorn A, van Essen HF, Cordes M, Fleischeuer R, Gijtenbeek AM, Beute G, van den Brink WA, Meijer GA, Havenith M, Idbaih A, Hoang-Xuan K, Mokhtari K, Verhaak RG, van der Valk P, van de Wiel MA, Heimans JJ, Aronica E, Reijneveld JC, Wesseling P, Ylstra B. Spatial and temporal evolution of distal 10q deletion, a prognostically unfavorable event in diffuse low-grade gliomas. Genome Biol. 2014 Sep 23;15(9):471. doi: 10.1186/s13059-014-0471-6. PubMed PMID: 25245118; PubMed Central PMCID: PMC4195855.

138: Sahm F, Reuss D, Koelsche C, Capper D, Schittenhelm J, Heim S, Jones DT, Pfister SM, Herold-Mende C, Wick W, Mueller W, Hartmann C, Paulus W, von Deimling A. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol. 2014 Oct;128(4):551-9. doi: 10.1007/s00401-014-1326-7. Epub 2014 Aug 21. PubMed PMID: 25143301.

139: Tabouret E, Chinot O, Sanson M, Loundou A, Hoang-Xuan K, Delattre JY, Idbaih A. Predictive biomarkers investigated in glioblastoma. Expert Rev Mol Diagn. 2014 Sep;14(7):883-93. doi: 10.1586/14737159.2014.945436. Epub 2014 Aug 5. Review. PubMed PMID: 25096963.

140: Haapasalo J, Hyartt A, Salmi M, Nordfors K, Lahtela SL, Kähkönen M, Helén P, Haapasalo H. [Diagnosis and prognosis of gliomas–current prospects of molecular diagnostics]. Duodecim. 2014;130(9):893-901. Review. Finnish. PubMed PMID: 24881141.

141: Polivka J Jr, Polivka J, Rohan V, Topolcan O. New treatment paradigm for patients with anaplastic oligodendroglial tumors. Anticancer Res. 2014 Apr;34(4):1587-94. Review. PubMed PMID: 24692686.

142: Gillet E, Alentorn A, Doukouré B, Mundwiller E, van Thuijl HF, Reijneveld JC, Medina JA, Liou A, Marie Y, Mokhtari K, Hoang-Xuan K, Sanson M, Delattre JY, Idbaih A. TP53 and p53 statuses and their clinical impact in diffuse low grade gliomas. J Neurooncol. 2014 May;118(1):131-9. doi: 10.1007/s11060-014-1407-4. Epub 2014 Mar 4. Erratum in: J Neurooncol. 2014 Aug;119(1):225. Van Thuij, Hinke [corrected to van Thuijl, Hinke F]. PubMed PMID: 24590827.

143: Haberler C, Wöhrer A. Clinical Neuropathology practice news 2-2014: ATRX, a new candidate biomarker in gliomas. Clin Neuropathol. 2014 Mar-Apr;33(2):108-11. PubMed PMID: 24559763; PubMed Central PMCID: PMC3967248.

144: Jiang HH, Ren XH, Zhang Z, Lin S. [A molecular classification system for anaplastic glioma]. Zhonghua Wai Ke Za Zhi. 2013 Dec;51(12):1104-9. Chinese. PubMed PMID: 24499721.

145: Torres-Martín M, Peña-Granero C, Carceller F, Gutiérrez M, Burbano RR, Pinto GR, Castresana JS, Melendez B, Rey JA. Homozygous deletion of TNFRSF4, TP73, PPAP2B and DPYD at 1p and PDCD5 at 19q identified by multiplex ligation-dependent probe amplification (MLPA) analysis in pediatric anaplastic glioma with questionable oligodendroglial component. Mol Cytogenet. 2014 Jan 6;7(1):1. doi: 10.1186/1755-8166-7-1. PubMed PMID: 24387276; PubMed Central PMCID: PMC3905963.

146: Jesionek-Kupnicka D, Szybka M, Potemski P, Kulczycka-Wojdala D, Jaskólski D, Bieńkowski M, Skowroński W, Papierz W, Kordek R, Zawlik I. Association of loss of heterozygosity with shorter survival in primary glioblastoma patients. Pol J Pathol. 2013 Dec;64(4):268-75. PubMed PMID: 24375041.

147: Reyes-Botero G, Dehais C, Idbaih A, Martin-Duverneuil N, Lahutte M, Carpentier C, Letouzé E, Chinot O, Loiseau H, Honnorat J, Ramirez C, Moyal E, Figarella-Branger D, Ducray F; POLA Network. Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression. Neuro Oncol. 2014 May;16(5):662-70. doi: 10.1093/neuonc/not235. Epub 2013 Dec 18. PubMed PMID: 24353325; PubMed Central PMCID: PMC3984545.

148: Jiang H, Ren X, Wang J, Zhang Z, Jia W, Lin S. Short-term survivors in glioblastomas with oligodendroglioma component: a clinical study of 186 Chinese patients from a single institution. J Neurooncol. 2014 Jan;116(2):395-404. doi: 10.1007/s11060-013-1311-3. Epub 2013 Nov 22. PubMed PMID: 24264532; PubMed Central PMCID: PMC3890040.

149: Nagaishi M, Suzuki A, Nobusawa S, Yokoo H, Nakazato Y. Alpha-internexin and altered CIC expression as a supportive diagnostic marker for oligodendroglial tumors with the 1p/19q co-deletion. Brain Tumor Pathol. 2014 Oct;31(4):257-64. doi: 10.1007/s10014-013-0168-7. Epub 2013 Nov 7. PubMed PMID: 24197863.

150: Takahashi Y, Nakamura H, Makino K, Hide T, Muta D, Kamada H, Kuratsu J. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World J Surg Oncol. 2013 Oct 25;11:284. doi: 10.1186/1477-7819-11-284. PubMed PMID: 24160898; PubMed Central PMCID: PMC3874767.

151: Eisenreich S, Abou-El-Ardat K, Szafranski K, Campos Valenzuela JA, Rump A, Nigro JM, Bjerkvig R, Gerlach EM, Hackmann K, Schröck E, Krex D, Kaderali L, Schackert G, Platzer M, Klink B. Novel CIC point mutations and an exon-spanning, homozygous deletion identified in oligodendroglial tumors by a comprehensive genomic approach including transcriptome sequencing. PLoS One. 2013 Sep 27;8(9):e76623. doi: 10.1371/journal.pone.0076623. eCollection 2013. PubMed PMID: 24086756; PubMed Central PMCID: PMC3785522.

152: Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Curr Treat Options Oncol. 2013 Dec;14(4):505-13. doi: 10.1007/s11864-013-0251-7. PubMed PMID: 23907441.

153: Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister SM, Platten M, Weller M, Wick W. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol. 2013 Sep;126(3):443-51. doi: 10.1007/s00401-013-1156-z. Epub 2013 Aug 1. PubMed PMID: 23904111.

154: Ren X, Jiang H, Cui X, Cui Y, Ma J, Jiang Z, Sui D, Lin S. Co-polysomy of chromosome 1q and 19p predicts worse prognosis in 1p/19q codeleted oligodendroglial tumors: FISH analysis of 148 consecutive cases. Neuro Oncol. 2013 Sep;15(9):1244-50. doi: 10.1093/neuonc/not092. Epub 2013 Jul 16. PubMed PMID: 23861470; PubMed Central PMCID: PMC3748924.

155: Hewer E, Beck J, Vassella E, Vajtai I. Anaplastic oligodendroglioma arising from the brain stem and featuring 1p/19q co-deletion. Neuropathology. 2014 Feb;34(1):32-8. doi: 10.1111/neup.12043. Epub 2013 May 27. PubMed PMID: 23711170.

156: Mizoguchi M, Hata N, Suzuki SO, Fujioka Y, Murata H, Amano T, Nakamizo A, Yoshimoto K, Iwaki T, Sasaki T. Pediatric glioblastoma with oligodendroglioma component: aggressive clinical phenotype with distinct molecular characteristics. Neuropathology. 2013 Dec;33(6):652-7. doi: 10.1111/neup.12029. Epub 2013 Mar 27. PubMed PMID: 23530875.

157: Zhang GB, Cui XL, Sui DL, Ren XH, Zhang Z, Wang ZC, Lin S. Differential molecular genetic analysis in glioblastoma multiforme of long- and short-term survivors: a clinical study in Chinese patients. J Neurooncol. 2013 Jun;113(2):251-8. doi: 10.1007/s11060-013-1102-x. Epub 2013 Mar 15. PubMed PMID: 23494873.

158: Boots-Sprenger SH, Sijben A, Rijntjes J, Tops BB, Idema AJ, Rivera AL, Bleeker FE, Gijtenbeek AM, Diefes K, Heathcock L, Aldape KD, Jeuken JW, Wesseling P. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution. Mod Pathol. 2013 Jul;26(7):922-9. doi: 10.1038/modpathol.2012.166. Epub 2013 Feb 22. PubMed PMID: 23429602.

159: Jiang H, Ren X, Zhang W, Ma J, Sui D, Jiang Z, Cui X, Lin S. A new prognostic scoring scale for patients with primary WHO grade III gliomas based on molecular predictors. J Neurooncol. 2013 Feb;111(3):367-75. doi: 10.1007/s11060-012-1026-x. Epub 2012 Dec 27. PubMed PMID: 23269453.

160: Lassman AB. Success at last: a molecular factor that informs treatment. Curr Oncol Rep. 2013 Feb;15(1):47-55. doi: 10.1007/s11912-012-0281-5. PubMed PMID: 23247800.

161: Idbaih A, Ducray F, Dehais C, Courdy C, Carpentier C, de Bernard S, Uro-Coste E, Mokhtari K, Jouvet A, Honnorat J, Chinot O, Ramirez C, Beauchesne P, Benouaich-Amiel A, Godard J, Eimer S, Parker F, Lechapt-Zalcman E, Colin P, Loussouarn D, Faillot T, Dam-Hieu P, Elouadhani-Hamdi S, Bauchet L, Langlois O, Le Guerinel C, Fontaine D, Vauleon E, Menei P, Fotso MJ, Desenclos C, Verrelle P, Ghiringhelli F, Noel G, Labrousse F, Carpentier A, Dhermain F, Delattre JY, Figarella-Branger D; POLA Network. SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas. PLoS One. 2012;7(10):e45950. doi: 10.1371/journal.pone.0045950. Epub 2012 Oct 10. Erratum in: PLoS One. 2013;8(5). doi:10.1371/annotation/27807b78-9c79-414a-a47e-fb3eca621be4. Verelle, Pierre [corrected to Verrelle, Pierre]. PubMed PMID: 23071531; PubMed Central PMCID: PMC3468603.

162: Kanamori M, Kumabe T, Shibahara I, Saito R, Yamashita Y, Sonoda Y, Suzuki H, Watanabe M, Tominaga T. Clinical and histological characteristics of recurrent oligodendroglial tumors: comparison between primary and recurrent tumors in 18 cases. Brain Tumor Pathol. 2013 Jul;30(3):151-9. doi: 10.1007/s10014-012-0119-8. Epub 2012 Oct 2. PubMed PMID: 23053495.

163: Hofer S. [Current concepts in Neuro-Oncology]. Ther Umsch. 2012 Oct;69(10):597-604. doi: 10.1024/0040-5930/a000336. German. PubMed PMID: 23026886.

164: Holdhoff M, Ye X, Blakeley JO, Blair L, Burger PC, Grossman SA, Diaz LA Jr. Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas. J Neurooncol. 2012 Nov;110(2):279-85. doi: 10.1007/s11060-012-0968-3. Epub 2012 Aug 29. PubMed PMID: 22930388.

165: Okita Y, Narita Y, Miyakita Y, Ohno M, Matsushita Y, Fukushima S, Sumi M, Ichimura K, Kayama T, Shibui S. IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy. Int J Oncol. 2012 Oct;41(4):1325-36. doi: 10.3892/ijo.2012.1564. Epub 2012 Jul 20. PubMed PMID: 22825915.

166: Chi AS, Batchelor TT, Dias-Santagata D, Borger D, Stiles CD, Wang DL, Curry WT, Wen PY, Ligon KL, Ellisen L, Louis DN, Iafrate AJ. Prospective, high-throughput molecular profiling of human gliomas. J Neurooncol. 2012 Oct;110(1):89-98. doi: 10.1007/s11060-012-0938-9. Epub 2012 Jul 22. PubMed PMID: 22821383; PubMed Central PMCID: PMC3583376.

167: Mizoguchi M, Yoshimoto K, Ma X, Guan Y, Hata N, Amano T, Nakamizo A, Suzuki SO, Iwaki T, Sasaki T. Molecular characteristics of glioblastoma with 1p/19q co-deletion. Brain Tumor Pathol. 2012 Jul;29(3):148-53. doi: 10.1007/s10014-012-0107-z. Epub 2012 Jun 27. PubMed PMID: 22736234.

168: Myung JK, Cho HJ, Park CK, Chung CK, Choi SH, Kim SK, Park SH. Clinicopathological and genetic characteristics of extraventricular neurocytomas. Neuropathology. 2013 Apr;33(2):111-21. doi: 10.1111/j.1440-1789.2012.01330.x. Epub 2012 Jun 4. Review. PubMed PMID: 22672632.

169: Paleologos NA, Merrell RT. Anaplastic glioma. Curr Treat Options Neurol. 2012 Aug;14(4):381-90. doi: 10.1007/s11940-012-0177-6. PubMed PMID: 22665140.

170: Badiali M, Gleize V, Paris S, Moi L, Elhouadani S, Arcella A, Morace R, Antonelli M, Buttarelli FR, Figarella-Branger D, Kim YH, Ohgaki H, Mokhtari K, Sanson M, Giangaspero F. KIAA1549-BRAF fusions and IDH mutations can coexist in diffuse gliomas of adults. Brain Pathol. 2012 Nov;22(6):841-7. doi: 10.1111/j.1750-3639.2012.00603.x. Epub 2012 Jun 18. PubMed PMID: 22591444.

171: Sahm F, Koelsche C, Meyer J, Pusch S, Lindenberg K, Mueller W, Herold-Mende C, von Deimling A, Hartmann C. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. Acta Neuropathol. 2012 Jun;123(6):853-60. doi: 10.1007/s00401-012-0993-5. Epub 2012 May 17. PubMed PMID: 22588899.

172: Ren X, Cui X, Lin S, Wang J, Jiang Z, Sui D, Li J, Wang Z. Co-deletion of chromosome 1p/19q and IDH1/2 mutation in glioma subsets of brain tumors in Chinese patients. PLoS One. 2012;7(3):e32764. doi: 10.1371/journal.pone.0032764. Epub 2012 Mar 12. PubMed PMID: 22427879; PubMed Central PMCID: PMC3299680.

173: Preusser M, Hoeftberger R, Woehrer A, Gelpi E, Kouwenhoven M, Kros JM, Sanson M, Idbaih A, Brandes AA, Heinzl H, Gorlia T, Hainfellner JA, van den Bent M. Prognostic value of Ki67 index in anaplastic oligodendroglial tumours–a translational study of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Histopathology. 2012 May;60(6):885-94. doi: 10.1111/j.1365-2559.2011.04134.x. Epub 2012 Feb 15. PubMed PMID: 22335622.

174: Mellai M, Monzeglio O, Piazzi A, Caldera V, Annovazzi L, Cassoni P, Valente G, Cordera S, Mocellini C, Schiffer D. MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors. J Neurooncol. 2012 May;107(3):617-31. doi: 10.1007/s11060-011-0787-y. PubMed PMID: 22287028.

175: Hegi ME, Janzer RC, Lambiv WL, Gorlia T, Kouwenhoven MC, Hartmann C, von Deimling A, Martinet D, Besuchet Schmutz N, Diserens AC, Hamou MF, Bady P, Weller M, van den Bent MJ, Mason WP, Mirimanoff RO, Stupp R, Mokhtari K, Wesseling P; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathol. 2012 Jun;123(6):841-52. doi: 10.1007/s00401-011-0938-4. Epub 2012 Jan 15. PubMed PMID: 22249618.

176: Iwadate Y, Matsutani T, Shinozaki N, Saeki N. Anaplastic oligodendroglial tumors harboring 1p/19q deletion can be successfully treated without radiotherapy. Anticancer Res. 2011 Dec;31(12):4475-9. PubMed PMID: 22199318.

177: Mukasa A, Takayanagi S, Saito K, Shibahara J, Tabei Y, Furuya K, Ide T, Narita Y, Nishikawa R, Ueki K, Saito N. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. Cancer Sci. 2012 Mar;103(3):587-92. doi: 10.1111/j.1349-7006.2011.02175.x. Epub 2012 Jan 13. PubMed PMID: 22136423.

178: Yip S, Butterfield YS, Morozova O, Chittaranjan S, Blough MD, An J, Birol I, Chesnelong C, Chiu R, Chuah E, Corbett R, Docking R, Firme M, Hirst M, Jackman S, Karsan A, Li H, Louis DN, Maslova A, Moore R, Moradian A, Mungall KL, Perizzolo M, Qian J, Roldan G, Smith EE, Tamura-Wells J, Thiessen N, Varhol R, Weiss S, Wu W, Young S, Zhao Y, Mungall AJ, Jones SJ, Morin GB, Chan JA, Cairncross JG, Marra MA. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol. 2012 Jan;226(1):7-16. doi: 10.1002/path.2995. Epub 2011 Nov 10. PubMed PMID: 22072542; PubMed Central PMCID: PMC3246739.

179: Mellai M, Piazzi A, Caldera V, Monzeglio O, Cassoni P, Valente G, Schiffer D. IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors. J Neurooncol. 2011 Nov;105(2):345-57. doi: 10.1007/s11060-011-0596-3. Epub 2011 Jun 4. PubMed PMID: 21643842.

180: Grauer O, Pascher C, Hartmann C, Zeman F, Weller M, Proescholdt M, Brawanski A, Pietsch T, Wick W, Bogdahn U, Hau P. Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05). J Neurooncol. 2011 Sep;104(3):801-9. doi: 10.1007/s11060-011-0548-y. Epub 2011 Mar 4. Erratum in: J Neurooncol. 2011 Dec;105(3):671. PubMed PMID: 21373969.

181: Furtado SV, Venkatesh PK, Ghosal N, Murthy GK, Hegde AS. Clinical and radiological features of pediatric cerebellar anaplastic oligodendrogliomas. Indian J Pediatr. 2011 Jul;78(7):880-3. doi: 10.1007/s12098-010-0318-4. Epub 2011 Jan 19. PubMed PMID: 21243536.

182: Hofer S, Lassman AB. Molecular markers in gliomas: impact for the clinician. Target Oncol. 2010 Sep;5(3):201-10. doi: 10.1007/s11523-010-0157-2. Epub 2010 Aug 31. Review. PubMed PMID: 20809335.

183: Iwadate Y, Matsutani T, Hasegawa Y, Shinozaki N, Higuchi Y, Saeki N. Favorable long-term outcome of low-grade oligodendrogliomas irrespective of 1p/19q status when treated without radiotherapy. J Neurooncol. 2011 May;102(3):443-9. doi: 10.1007/s11060-010-0340-4. Epub 2010 Aug 19. PubMed PMID: 20721680.

184: Sherman JH, Prevedello DM, Shah L, Raghavan P, Pouratian N, Starke RM, Lopes MB, Shaffrey ME, Schiff D. MR imaging characteristics of oligodendroglial tumors with assessment of 1p/19q deletion status. Acta Neurochir (Wien). 2010 Nov;152(11):1827-34. doi: 10.1007/s00701-010-0743-1. Epub 2010 Aug 15. PubMed PMID: 20711790.

185: Wu A, Aldape K, Lang FF. High rate of deletion of chromosomes 1p and 19q in insular oligodendroglial tumors. J Neurooncol. 2010 Aug;99(1):57-64. doi: 10.1007/s11060-009-0100-5. Epub 2009 Dec 25. PubMed PMID: 20035368; PubMed Central PMCID: PMC2891585.

186: Yang SH, Kim YH, Kim JW, Park CK, Park SH, Jung HW. Methylation Status of the O6-Methylguanine-Deoxyribonucleic Acid Methyltransferase Gene Promoter in World Health Organization Grade III Gliomas. J Korean Neurosurg Soc. 2009 Oct;46(4):385-8. doi: 10.3340/jkns.2009.46.4.385. Epub 2009 Oct 31. PubMed PMID: 19893731; PubMed Central PMCID: PMC2773399.

187: Wang Y, Xiong J, Chu SG, Liu Y, Cheng HX, Wang YF, Zhao Y, Mao Y. Rosette-forming glioneuronal tumor: report of an unusual case with intraventricular dissemination. Acta Neuropathol. 2009 Dec;118(6):813-9. doi: 10.1007/s00401-009-0569-1. PubMed PMID: 19585134.

188: Dunbar EM. The role of chemotherapy for pure and mixed anaplastic oligodendroglial tumors. Curr Treat Options Oncol. 2009 Aug;10(3-4):216-30. doi: 10.1007/s11864-009-0091-7. Epub 2009 Apr 18. Review. PubMed PMID: 19381820.

189: Benetkiewicz M, Idbaih A, Cousin PY, Boisselier B, Marie Y, Crinière E, Hoang-Xuan K, Delattre JY, Sanson M, Delattre O. NOTCH2 is neither rearranged nor mutated in t(1;19) positive oligodendrogliomas. PLoS One. 2009;4(1):e4107. doi: 10.1371/journal.pone.0004107. Epub 2009 Jan 1. PubMed PMID: 19119320; PubMed Central PMCID: PMC2606061.

190: Roldán G, Scott J, George D, Parney I, Easaw J, Cairncross G, Forsyth P, Yan E. Leptomeningeal disease from oligodendroglioma: clinical and molecular analysis. Can J Neurol Sci. 2008 May;35(2):204-9. PubMed PMID: 18574935.

191: Campbell BA, Horsman DE, Maguire J, Young S, Curman D, Ma R, Thiessen B. Chromosomal alterations in oligodendroglial tumours over multiple surgeries: is tumour progression associated with change in 1p/19q status? J Neurooncol. 2008 Aug;89(1):37-45. doi: 10.1007/s11060-008-9597-2. Epub 2008 May 6. PubMed PMID: 18458822.

192: Carrato-Monino C, Ariza A. [Oligodendrogliomas: their morphological characteristics and molecular alterations]. Rev Neurol. 2007 Mar 16-31;44(6):353-9. Review. Spanish. PubMed PMID: 17385172.

1p_19q_co-deletion_unclassified.txt · Last modified: 2019/11/30 12:16 by administrador